Malte Renz (Stanford University S Division of Gynecologic Oncology, Elisabeth Diver (Stanford Univers Division of Gynecologic Oncology, Whitfield Growdon (NYU Grossman S Division of Gynecologic Oncology

Synopsis of Key Gynecologic Oncology Trials

• Broschiertes Buch

Produktbeschreibung

This revised and updated new edition of a best-selling text remains a fast and convenient overview of the clinical trials in gynecologic cancer treatment, outlining the evidence base of treatment decisions in uterine, ovarian, cervical, and vulvar cancers, and gestational trophoblastic neoplasia.

Produktdetails

• Verlag: Taylor & Francis Ltd
• 2 ed
• Seitenzahl: 160
• Erscheinungstermin: 6. Dezember 2022
• Englisch
• Abmessung: 151mm x 229mm x 15mm
• Gewicht: 262g
• ISBN-13: 9781032135328
• ISBN-10: 1032135328
• Artikelnr.: 64629407

Autorenporträt

Malte Renz, MD, PhD: Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, California, USA Elisabeth J. Diver, MD: Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, California, USA Whitfield B. Growdon, MD: Division of Gynecologic Oncology, NYU Grossman School of Medicine, New York, New York, USA Oliver Dorigo, MD, PhD: Division of Gynecologic Oncology, Stanford University School of Medicine, Standford, California, USA

Inhaltsangabe

Preface to the second edition
1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies
addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2.
Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2.
Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment
of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2.
Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2.
Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2.
Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment
of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma.
1.3.1. Studies addressing adjuvant treatment of early stage uterine
leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine
leiomyosarcoma. 1.4. References.
2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1.
Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant
therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4.
Studies addressing first line maintenance treatment. 2.1.5. Studies
addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of
debulking. 2.1.7. Studies addressing time point of treatment of recurrence.
2.1.8. Studies addressing treatment of recurrent ovarian cancer,
platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2.
Secondary debulking surgery. 2.1.9. Studies addressing treatment of
recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and
targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian
cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ
Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6.
References.
3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2.
Studies addressing adjuvant therapy. 3.3. Studies addressing primary
chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or
metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy.
3.4.2. Immunotherapy. 3.5. References.
4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin
lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1.
Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.
5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing
surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN.
5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.
6. Glossary. Index.